AR126749A1 - Tratamiento de la dermatitis atópica - Google Patents

Tratamiento de la dermatitis atópica

Info

Publication number
AR126749A1
AR126749A1 ARP220102143A ARP220102143A AR126749A1 AR 126749 A1 AR126749 A1 AR 126749A1 AR P220102143 A ARP220102143 A AR P220102143A AR P220102143 A ARP220102143 A AR P220102143A AR 126749 A1 AR126749 A1 AR 126749A1
Authority
AR
Argentina
Prior art keywords
antigen
treatment
atopic dermatitis
antibody
ox40l
Prior art date
Application number
ARP220102143A
Other languages
English (en)
Spanish (es)
Inventor
Ben Porter-Brown
Sonia Quaratino
Richard C A Sainson
John Powell
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2115152.7A external-priority patent/GB202115152D0/en
Priority claimed from GBGB2204211.3A external-priority patent/GB202204211D0/en
Priority claimed from GBGB2204291.5A external-priority patent/GB202204291D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of AR126749A1 publication Critical patent/AR126749A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ARP220102143A 2021-08-10 2022-08-09 Tratamiento de la dermatitis atópica AR126749A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB202111492 2021-08-10
GBGB2115152.7A GB202115152D0 (en) 2021-10-21 2021-10-21 Treatment of atopic dermatitis
GBGB2204211.3A GB202204211D0 (en) 2022-03-24 2022-03-24 Treatment of atopic dermatitis
GBGB2204291.5A GB202204291D0 (en) 2022-03-25 2022-03-25 Treatment of atopic dermatitis

Publications (1)

Publication Number Publication Date
AR126749A1 true AR126749A1 (es) 2023-11-08

Family

ID=82942548

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102143A AR126749A1 (es) 2021-08-10 2022-08-09 Tratamiento de la dermatitis atópica

Country Status (11)

Country Link
US (2) US20230235069A1 (https=)
EP (1) EP4384270A1 (https=)
JP (1) JP2024530954A (https=)
KR (1) KR20240043789A (https=)
AR (1) AR126749A1 (https=)
AU (1) AU2022326849A1 (https=)
CA (1) CA3228708A1 (https=)
IL (1) IL310701A (https=)
MX (1) MX2024001877A (https=)
TW (1) TW202330023A (https=)
WO (1) WO2023017252A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260026080A (ko) * 2023-06-20 2026-02-25 키맵 리미티드 면역 매개 질환의 투여 및 치료와 면역 매개 질환과 관련된 바이오마커
WO2025090570A1 (en) * 2023-10-23 2025-05-01 Abcellera Biologics Inc. Anti-ox40l antibodies and methods of use
WO2025233445A1 (en) * 2024-05-08 2025-11-13 Kymab Limited Treatment of head and neck atopic dermatitis
WO2025255353A1 (en) * 2024-06-06 2025-12-11 Apogee Therapeutics, Inc. Dosage and administration of an anti-ox40l antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2426744C2 (ru) * 2005-12-16 2011-08-20 Дженентек, Инк. Антитела к ox40l и способы их применения
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2513145B1 (en) * 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN107074951B (zh) * 2014-08-04 2021-08-03 贝勒研究院 拮抗性抗-ox40l抗体及其使用方法
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods

Also Published As

Publication number Publication date
EP4384270A1 (en) 2024-06-19
US20230235069A1 (en) 2023-07-27
TW202330023A (zh) 2023-08-01
MX2024001877A (es) 2024-02-28
JP2024530954A (ja) 2024-08-27
WO2023017252A1 (en) 2023-02-16
IL310701A (en) 2024-04-01
US20250353918A1 (en) 2025-11-20
AU2022326849A1 (en) 2024-03-21
CA3228708A1 (en) 2023-02-16
KR20240043789A (ko) 2024-04-03

Similar Documents

Publication Publication Date Title
AR126749A1 (es) Tratamiento de la dermatitis atópica
CL2020002143A1 (es) Dominios variables de anticuerpo que se dirigen a cd33 y sus usos. (solic hna 2144)
AR034429A1 (es) Uso de una composicion que contiene un anticuerpo anti-tnf alfa en la fabricacion de un medicamento y equipo y jeringa cargada, conteniendo dicha composicion.
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
FI3515937T3 (fi) Refraktaarisen migreenin hoito
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
JP2019509988A5 (https=)
ECSP17005649A (es) Anticuerpos anti-tau humanizados
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
ECSP13012792A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
BR112021009856A8 (pt) Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
AR082390A1 (es) Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2021004994A (es) Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2019014831A (es) Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9.
MX2022004268A (es) Cartucho para un autoinyector y metodos relacionados.
CL2024002016A1 (es) Anticuerpo modificado anti-pd-l1 humano; composición farmacéutica; y uso para tratar una enfermedad neurodegenerativa.
RU2012108108A (ru) Концентрированные полипептидные лекарственные формы с пониженной вязкостью
MX2022001065A (es) Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.